Tong Guang, Zhang Ben, Zhou Xuan, Zhao Jinbo, Sun Zhongchan, Tao Ye, Pei Jianming, Zhang Weida
Department of Cardiovascular Surgery, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China.
Cell Physiol Biochem. 2016;39(6):2158-2172. doi: 10.1159/000447911. Epub 2016 Nov 2.
BACKGROUNDS/AIMS: The selective κ-opioid agonist U50,488H protects heart from myocardial ischemia-reperfusion (MI/R) injury. We examined whether U50,488H is also beneficial for MI/R induced heart failure.
Anesthetized male Sprague-Dawley rats were subjected to 30 min of myocardial ischemia via left anterior descending coronary artery (LAD) occlusion, followed by 4 weeks of reperfusion. Infarct size was examined by Evans blue/triphenyl tetrazolium chloride (TTC) staining. Cardiac function and remodeling were examined by echocardiography and histology. HO-1 gene transcription and expression were measured by RT-PCR and western blot.
Compared to vehicle-treated MI/R rats, rats administered a single dose of U50,488H at the beginning of reperfusion exhibited reduced myocardial infarct size, oxidative stress, hypertrophy, and fibrosis, improved mechanical function, and greater neovascularization. U50,488H also increased myocardial heme oxygenase (HO)-1 gene transcription and expression, while pharmacological HO-1 inhibition reversed all protective effects of U50,488H. Furthermore, U50,488H protected control cultured cardiomyoctes against simulated I/R-induced apoptosis but not cultures subjected to shRNA-mediated HO-1 knockdown. Inhibition of HO-1 in the subacute phase of reperfusion reversed the U50,488H-induced increase in neovascularization and suppression of oxidative stress. Finally, U50,488H increased Akt phosphorylation and nuclear translocation of Nrf2, a key HO-1 transcription activator, while inhibition of PI3K-Akt signaling abolished U50,488H-induced Nrf2 nuclear translocation, HO-1 upregulation, and cardioprotection.
Activation of HO-1 expression through the PI3K-Akt-Nrf2 pathway may mediate the acute and long-term protective effects of U50,488H against heart failure by enhancing cardiomyocyte survival and neoangiogenesis and by reducing oxidative stress.
背景/目的:选择性κ-阿片受体激动剂U50,488H可保护心脏免受心肌缺血再灌注(MI/R)损伤。我们研究了U50,488H对MI/R诱导的心力衰竭是否也有益。
对麻醉的雄性Sprague-Dawley大鼠通过左冠状动脉前降支(LAD)闭塞进行30分钟心肌缺血,随后再灌注4周。通过伊文思蓝/氯化三苯基四氮唑(TTC)染色检查梗死面积。通过超声心动图和组织学检查心脏功能和重塑。通过逆转录聚合酶链反应(RT-PCR)和蛋白质印迹法测量血红素加氧酶-1(HO-1)基因转录和表达。
与给予赋形剂的MI/R大鼠相比,在再灌注开始时单次给予U50,488H的大鼠心肌梗死面积减小、氧化应激减轻、肥大和纤维化减轻、机械功能改善且新生血管形成增多。U50,488H还增加心肌血红素加氧酶(HO)-1基因转录和表达,而药理学上抑制HO-1可逆转U50,488H的所有保护作用。此外,U50,488H保护对照培养的心肌细胞免受模拟I/R诱导的凋亡,但对经短发夹RNA(shRNA)介导的HO-1基因敲低的培养细胞无效。在再灌注亚急性期抑制HO-1可逆转U50,488H诱导的新生血管形成增加和氧化应激抑制。最后,U50,488H增加Akt磷酸化和关键HO-1转录激活因子Nrf2的核转位,而抑制磷脂酰肌醇-3激酶(PI3K)-Akt信号通路可消除U50,488H诱导的Nrf2核转位、HO-1上调和心脏保护作用。
通过PI3K-Akt-Nrf2途径激活HO-1表达可能通过增强心肌细胞存活和新生血管形成以及减轻氧化应激来介导U50,488H对心力衰竭的急性和长期保护作用。